Stelara – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach

2 months ago talkbio0Tagged Bioepis, Biosimilars, Contract agreement, Johnson and Johnson, Pyzchiva, Samsung, Stelara, ustekinumab

Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva

Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline

6 months ago talkbio0Tagged Carvykti, Darzalex, Johnson and Johnson, Neoplasms, Pharmaceutical Sales, Stelara

Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales

Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial

6 months ago talkbio0Tagged Crohn 's disease, Eli, Eli Lilly, Inflammatory Bowel Diseases, mirikizumab, Phase 3 Clinical Trials, Stelara, ustekinumab

Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson

Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS

8 months ago talkbio0Tagged 340B, CHARGE Syndrome, drug discount program, HHS, hospital payments, HRSA, Johnson and Johnson, Stelara

Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments

Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data

11 months ago talkbio0Tagged Biological Factors, Clinical Trials, head-to-head data, J&J, Psoriasis, Stelara, successor, Tremfya

J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.